Why the study?
Delayed platelet engraftment and thrombocytopenia are common, high-risk complications after myeloablative allo-HCT, making strategies to promote haematopoietic reconstitution critical for improving outcomes.
Does recombinant human thrombopoietin reduce platelet engraftment time in patients undergoing allogeneic haematopoietic cell transplantation?
Population
210 patients who underwent allo-HCT
Comparison
rhTPO vs control
Design
Retrospective study
Follow-up
2 years
Authors
Loading...
rhTPO may accelerate platelet recovery post-allo-HCT; hypothesis-generating, prospective trials needed before practice change.
Does recombinant human thrombopoietin reduce platelet engraftment time in patients undergoing allogeneic haematopoietic cell transplantation?
Recombinant human thrombopoietin safely and effectively reduces the time required for platelet and granulocyte engraftment after allogeneic haematopoietic cell transplantation.
Tian et al. (2024) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: